Pharmacology · Receptor biology · continued
Follow-up: Why appetite effects are mostly central posts 91–91
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
This topic was referenced in
- GIP receptor agonism and the argument about direction — does this still hold?Pharmacology › Receptor biology · 14 replies
This topic was closed 30 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…
|
+52 | 57 | 25k | just now |
|
Why appetite effects are mostly central
Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Posting the method first, because I know what the first three replies will…
|
2 | 56k | 16mo | |
|
Glucagon receptor agonism in a weight-loss compound
On the subject in the title: Glucagon receptor agonism in a weight-loss compound Working notes rather than a conclusion. Posting the method first, because I know what the first three replies will otherwise…
|
2 | 5.1k | 20mo | |
|
GLP-1 receptor distribution: central and peripheral — one year on
GLP-1 receptor distribution: central and peripheral — one year on — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…
|
+7 | 11 | 43k | 3mo |
|
Amylin receptor signalling and satiety — what changed since
On the subject in the title: Amylin receptor signalling and satiety — what changed since Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in…
|
+73 | 78 | 3.5k | 2mo |
Related topics — sharing the tags tirzepatide, retatrutide, semaglutide
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Books and papers worth reading that are not about this at all
On the subject in the title: Books and papers worth reading that are not about this at all Working notes rather than a conclusion. Lower-stakes topic, but the sourcing rule still applies if anyone makes a…
|
+13 | 17 | 13k | 19mo |
|
Second pass at: Reading a combination trial: attributing effect to components
Second pass at: Reading a combination trial: attributing effect to components — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in support of…
|
+39 | 43 | 7.3k | 12mo |
|
The most common factual error about semaglutide on the internet
On the subject in the title: The most common factual error about semaglutide on the internet Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the…
|
2 | 49k | 2y | |
|
Amylin analogue mechanism: satiety signalling separate from GLP-1
Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SCALE ( N Engl J Med , 2015) and…
|
+128 | 142 | 38k | 13mo |
|
[2026 update] Comparing tirzepatide and semaglutide is harder than the tables suggest
Comparing tirzepatide and semaglutide is harder than the tables suggest Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021) with SURMOUNT-1…
|
2 | 23k | 21mo |